--- title: "HCW Biologics Inc. (HCWB.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/HCWB.US.md" symbol: "HCWB.US" name: "HCW Biologics Inc." industry: "Biotechnology" datetime: "2026-04-30T12:10:19.902Z" locales: - [en](https://longbridge.com/en/quote/HCWB.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/HCWB.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/HCWB.US.md) --- # HCW Biologics Inc. (HCWB.US) ## Company Overview HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.hcwbiologics.com](https://www.hcwbiologics.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-04-30T04:30:16.000Z **Overall: D (0.74)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 328 / 389 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -97.89% | | | Net Profit YoY | 25.73% | | | P/B Ratio | 0.99 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 2744147.38 | | | Revenue | 54232.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 1113.43% | A | | Profit Margin | -14677.14% | E | | Gross Margin | 20.00% | D | | Revenue YoY | -97.89% | E | | Net Profit YoY | 25.73% | B | | Total Assets YoY | -18.91% | E | | Net Assets YoY | 140.84% | A | | Cash Flow Margin | 60.06% | C | | OCF YoY | -97.89% | E | | Turnover | 0.00 | E | | Gearing Ratio | 88.72% | E | ```chart-data:radar { "title": "Longbridge Financial Score - HCW Biologics Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-97.89%", "rating": "" }, { "name": "Net Profit YoY", "value": "25.73%", "rating": "" }, { "name": "P/B Ratio", "value": "0.99", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "2744147.38", "rating": "" }, { "name": "Revenue", "value": "54232.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "1113.43%", "rating": "A" }, { "name": "Profit Margin", "value": "-14677.14%", "rating": "E" }, { "name": "Gross Margin", "value": "20.00%", "rating": "D" }, { "name": "Revenue YoY", "value": "-97.89%", "rating": "E" }, { "name": "Net Profit YoY", "value": "25.73%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-18.91%", "rating": "E" }, { "name": "Net Assets YoY", "value": "140.84%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "60.06%", "rating": "C" }, { "name": "OCF YoY", "value": "-97.89%", "rating": "E" }, { "name": "Turnover", "value": "0.00", "rating": "E" }, { "name": "Gearing Ratio", "value": "88.72%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.12 | 97/389 | - | - | - | | PB | 0.99 | 98/389 | 0.97 | 0.50 | 0.39 | | PS (TTM) | 50.60 | 236/389 | 11.65 | 8.00 | 5.21 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A | | 03 | MiMedx (MDXG.US) | A | B | A | B | B | A | | 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A | | 05 | OpGen (OPGN.US) | B | A | A | A | C | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-03-17T04:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Overweight | 1 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 0.41 | | Highest Target | 2.00 | | Lowest Target | 2.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HCWB.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HCWB.US/norm.md) - [Related News](https://longbridge.com/en/quote/HCWB.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HCWB.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**